Recombinant TNFRSF8 (Brentuximab Biosimilar) antibody

Catalog No. ABIN7581724

The Human Monoclonal anti-TNFRSF8 (Brentuximab Biosimilar) antibody has been validated for ELISA, BLI, FACS, Func and SPR. It is suitable to detect TNFRSF8 (Brentuximab Biosimilar) in samples from Human.

Quick Overview for Recombinant TNFRSF8 (Brentuximab Biosimilar) antibody (ABIN7581724)

Target: TNFRSF8 (Brentuximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: This TNFRSF8 (Brentuximab Biosimilar) antibody is un-conjugated

Application: ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Product Details anti-TNFRSF8 (Brentuximab Biosimilar) Antibody

Expression System: CHO Cells

Purpose: Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab)

Sequence: QIQLQQSGPE VVKPGASVKI SCKASGYTFT DYYITWVKQK PGQGLEWIGW IYPGSGNTKY NEKFKGKATL TVDTSSSTAF MQLSSLTSED TAVYFCANYG NYWFAYWGQG TQVTVSAAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG,DIVLTQSPAS LAVSLGQRAT ISCKASQSVD FDGDSYMNWY QQKPGQPPKV LIYAASNLES GIPARFSGSG SGTDFTLNIH PVEEEDAATY YCQQSNEDPW TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC

Characteristics: Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.38 kDa.

Purity: >95 %

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Therapeutic Agents by Target and Mechanism: CD30 inhibitors

Conditions: Anaplastic Large Cell Lymphoma Hematologic malignancies Hodgkin Lymphoma

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: 1 mg/mL

Buffer: 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

Storage: 4 °C,-80 °C

Storage Comment: +4°C,-80°C

Target Details for TNFRSF8 (Brentuximab Biosimilar)

Target: TNFRSF8 (Brentuximab Biosimilar)

Target Type: Biosimilar

Background: Synonyms: TNFRSF8

Molecular Weight: 145.38 kDa

UniProt: P28908